Keros Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
92
- Stock Symbol
-
KROS
- Share Price
-
$11.39
- (As of Thursday Closing)
Keros Therapeutics General Information
Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Contact Information
Website
www.kerostx.comCorporate Office
- 99 Hayden Avenue
- Suite 120 (Building E)
- Lexington, MA 02421
- United States
Corporate Office
- 99 Hayden Avenue
- Suite 120 (Building E)
- Lexington, MA 02421
- United States
Keros Therapeutics Stock Performance
As of 19-Nov-2026, Keros Therapeutics’s stock price is $11.39. Its current market cap is $224M with 19.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.39 | $12.00 | $8.98 - $22.55 | $224M | 19.6M | 196K | -$2.80 |
Keros Therapeutics Financials Summary
As of 30-Sep-2026, Keros Therapeutics has a trailing 12-month revenue of $40.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (15,852) | (55,754) | 129,834 | 917,607 |
| Revenue | 40,761 | 244,061 | 3,550 | 151 |
| EBITDA | (60,879) | 93,406 | (185,824) | (152,177) |
| Net Income | (61,726) | 87,014 | (187,353) | (152,992) |
| Total Assets | 307,371 | 338,021 | 615,886 | 370,025 |
| Total Debt | 15,110 | 16,883 | 18,861 | 14,444 |
Keros Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Keros Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Keros Therapeutics Comparisons
Industry
Financing
Details
Keros Therapeutics Competitors (38)
One of Keros Therapeutics’s 38 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| U.S. Stem Cell | Formerly VC-backed | Sunrise, FL | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| BioCardia | Formerly VC-backed | Sunnyvale, CA |
Keros Therapeutics Patents
Keros Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236607-A1 | Methods of using activin receptor type ii variants | Pending | 08-May-2025 | ||
| WO-2025184284-A1 | Methods of using activin receptor type ii signaling inhibitors | Pending | 27-Feb-2024 | ||
| WO-2025174995-A1 | Methods of using activin a and myostatin signaling inhibitors | Pending | 13-Feb-2024 | ||
| WO-2025147483-A1 | Methods of using activin receptor type ii chimeras | Inactive | 02-Jan-2024 | ||
| AU-2024396254-A1 | Methods of using activin receptor type ii signaling inhibitors | Pending | 08-Dec-2023 | C07K14/71 |
Keros Therapeutics Signals
Keros Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Keros Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.77 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Keros Therapeutics FAQs
-
When was Keros Therapeutics founded?
Keros Therapeutics was founded in 2015.
-
Where is Keros Therapeutics headquartered?
Keros Therapeutics is headquartered in Lexington, MA.
-
What is the size of Keros Therapeutics?
Keros Therapeutics has 92 total employees.
-
What industry is Keros Therapeutics in?
Keros Therapeutics’s primary industry is Biotechnology.
-
Is Keros Therapeutics a private or public company?
Keros Therapeutics is a Public company.
-
What is Keros Therapeutics’s stock symbol?
The ticker symbol for Keros Therapeutics is KROS.
-
What is the current stock price of Keros Therapeutics?
As of 19-Nov-2026 the stock price of Keros Therapeutics is $11.39.
-
What is the current market cap of Keros Therapeutics?
The current market capitalization of Keros Therapeutics is $224M.
-
What is Keros Therapeutics’s current revenue?
The trailing twelve month revenue for Keros Therapeutics is $40.8M.
-
Who are Keros Therapeutics’s competitors?
Dyne Therapeutics, Arrowhead Pharmaceuticals, U.S. Stem Cell, Alnylam Pharmaceuticals, and BioCardia are some of the 38 competitors of Keros Therapeutics.
-
What is Keros Therapeutics’s annual earnings per share (EPS)?
Keros Therapeutics’s EPS for 12 months was -$2.80.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process